E-Mail:
Password:
Home | Stock Market Blogs | Financial Tools | Sign Up Free
 

Biotechnology Market Sector
More Pages: Page: 1 2 3 4 5 (6) 7 8 9 10 11
NASDAQ:MTXXMATRIXX INITIATIVES
 Matrixx Initiatives develops, produces, markets and sells over-the-counter healthcare products focused on those which utilize unique or novel delivery systems. Through its subsidiary, Zicam, LLC, Co. produces, markets and sells products under the Zicam and Nasal Comfort brands. As of Mar 31 2007, Co.'s product offerings consisted of: Zicam Cold Remedy product line; Zicam products for allergy/sinus; Seven Zicam Cough Mist products; Zicam Flu relief products; and Nasal Comfort moisture therapy products. Co. sells its products directly to food, drug, mass market and wholesale warehouse retailers throughout the U.S, and to distributors that sell to smaller retail establishments.
 Market CapDay's VolumeLast TradeChange
 $148M188,117$4.88-1.613%
 
NASDAQ:MAXYMaxygen
 Maxygen is a biotechnology company focused on the discovery and development of improved protein pharmaceuticals for the treatment of disease and serious medical conditions. As of Dec 31 2006, Co. had four product candidates in pre-clinical development: MAXY-G34 , a granulocyte colony stimulating factor (G-CSF) for the treatment of neutropenia; MAXY-alpha , an interferon alpha product for the treatment of hepatitis C virus infection; MAXY-VII , a factor VII product for the treatment of uncontrolled bleeding in trauma, intracerebral hemorrhage and other indications; and MAXY-gamma , an interferon gamma product for the treatment of idiopathic pulmonary fibrosis and other indications.
 Market CapDay's VolumeLast TradeChange
 $237M88,745$5.91-2.1524%
 
NASDAQ:MEDXMEDAREX
 Medarex is a biopharmaceutical company engaged in developing therapeutic products for cancer, inflammation, autoimmune disorders and other life-threatening and debilitating diseases based on its proprietary technology, the UltiMAb Human Antibody Development System . As of Dec 31 2006, 34 antibody product candidates generated from Co.'s UltiMAb Human Antibody Development System are in human clinical trials or had regulatory applications submitted for such trials, with seven product candidates in which it had an economic interest through co-promotion/profit sharing rights, royalties and/or equity ownership, under Phase III trials.
 Market CapDay's VolumeLast TradeChange
 -0$16.020.0%
 
AMEX:MCUMedicure, Inc.
 Medicure is engaged in the discovery and development of cardiovascular therapeutics and is in the research and development phase of its lead product, MC-1 and MC-4232.
 Market CapDay's VolumeLast TradeChange
 -0$0.03410.0%
 
NYSE:MEDMedifast, Inc.
 Medifast is engaged in the production, distribution, and sale of weight management and disease management products and other consumable health and diet products. Co.'s operations are conducted through its five wholly owned subsidiaries: Jason Pharmaceuticals, Inc., Take Shape for Life, Inc., Jason Enterprises, Inc., Jason Properties, LLC and Seven Crondall, LLC. Co.'s product lines include weight and disease management, meal replacement and sports nutrition products manufactured in the U.S. Food and Drug Administration approved facility in Owings Mills, MD. These products are sold through various channels of distribution, to include web, medical professionals, and weight loss clinics.
 Market CapDay's VolumeLast TradeChange
 -839,576$29.74-5.8563%
 
NASDAQ:MTOXMEDTOX SCIENTIFIC
 Medtox Scientific has two reportable segments: Laboratory Services, which is conducted by Co.'s MEDTOX Laboratories, Inc. subsidiary; and Products Sales, which is conducted by Co.'s MEDTOX Diagnostics, Inc. subsidiary. Co.'s Laboratory Services segment includes forensic toxicology, clinical toxicology, clinical testing for the pharmaceutical industry (central laboratory services, bioanalytical and pharmacokinetic testing), and analysis of heavy and trace metals. This segment also provides logistical support, data management and overall program management services. In addition, Co.'s Product Sales segment includes sales of a variety of on-site screening products and contract manufacturing.
 Market CapDay's VolumeLast TradeChange
 -53,041$11.65+0.8658%
 
OTC PK:MRPIMera Pharmaceuticals, Inc.
 Mera Pharmaceuticals develops and commercializes natural products derived principally from microalgae using its patented photobioreactor technology known as the Mera Growth Module. Microalgae are a diverse group of microscopic plants estimated to consist of more than 30,000 species. They have a range of physiological and biochemical characteristics. Microalgae produce many different substances and bioactive compounds that have existing and potential applications in a variety of commercial areas, including human nutrition, pharmaceuticals, and other high value commodities.
 Market CapDay's VolumeLast TradeChange
 $5M0$0.00780.0%
 
NASDAQ:VIVOMERIDIAN BIOSCIENCE
 Meridian Bioscience is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits, primarily for certain respiratory, gastrointestinal, viral and parasitic infectious diseases; the manufacture and distribution of bulk antigens and reagents used by researchers and other diagnostic manufacturers; and the contract manufacture of proteins and other biologicals for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. As of Sep 30 2007, Co. conducted its operations in three business segments: U.S. Diagnostics, European Diagnostics, and Life Science.
 Market CapDay's VolumeLast TradeChange
 $1,369M130,485$19.59-0.6089%
 
OTC PK:MTBRMetabolic Research, Inc.
 Metabolic Research is a biotechnology company developing a new form of pharmaceutical-grade non-synthetic pharmaceuticals to safely and effectively treat cancer, heart disease and metabolic and inflammatory diseases. Co.'s proprietary process is based on "growing" drugs by using natural metabolic processes of plants or fungus rather than chemical sythesis used by traditional pharmaceutical companies. Co.'s research in metabolic pharmaceuticals is still in the initial phase and preliminary reseach suggests this process could be used to develop safe and highly effective naturally produced pharmaceutical-grade substances to fight various diseases.
 Market CapDay's VolumeLast TradeChange
 -0$0.0220.0%
 
OTC PK:MCHUMicroholdings US Inc New
 Microholdings US is a holding company. Co.'s subsidiary West Coast Video Inc, owns and operates three video stores in Las Vegas, NV. Co. intends to design and develop a new online video rental service through West Coast Video. Co.'s subsidiaries XchangeTel, Inc and GDS Global Destination Services, Gmbh are providers of telecom and international carrier services.
 Market CapDay's VolumeLast TradeChange
 -0$0.0220.0%
 
NASDAQ:MITIMICROMET
 Micromet is a biopharmaceutical company developing antibody-based products for cancer, inflammatory and autoimmune diseases. As of Dec 31 2006, two of its product candidates are in clinical trials, while the remainder is in preclinical development. MT103, Co.'s first product candidate based on its BiTE product development platform, is being evaluated in a phase I clinical trial for the treatment of patients with non-Hodgkins lymphoma. Adecatumumab, a recombinant human monoclonal antibody, which targets Epithelial Cell Adhesion Molecule (EpCAM) expressing tumors, has completed two phase 2a clinical trials, one in patients with breast cancer and the other in patients with prostate cancer.
 Market CapDay's VolumeLast TradeChange
 -199,770$6.88-2.6875%
 
OTCBB:MKRSMikros Systems Corporation
 Mikros Systems is focused on the research and development of electronic systems technology primarily for military applications. Co.'s capabilities include technology management, electronic systems engineering and integration, radar systems engineering, combat/command, control, communications, computers and intelligence systems engineering, and communications engineering. Co. also focuses on developing technology and products, enhancing the military radio frequency and underwater data communications. Co.'s digital signal processing technology has enabled it to develop high-speed data broadcasting techniques utilizing the commercial amplitude modulation and frequency modulation radio wave.
 Market CapDay's VolumeLast TradeChange
 -18,000$0.200.0%
 
OTCBB:MBTGMillennium Biotechnologies Group, Inc.
 Millennium Biotechnologies Group is a holding company. Through its subsidiary, Co. is a research based bio-nutraceutical corporation involved in the field of nutritional science. Co.'s principal source of revenue is from sales of its nutraceutical supplements, RESURGEX SELECT , RESURGEX , and RESURGEX Plus . These three products create the Resurgex product line and are used by immuno-compromised individuals undergoing medical treatment for chronic debilitating diseases, healthy people searching for proper nutrition, and both amateur and professional athletes.
 Market CapDay's VolumeLast TradeChange
 -0$0.0160.0%
 
NASDAQ:MNTAMOMENTA PHARMA
 Momenta Pharmaceuticals is a biotechnology company engaged in the structural analysis of mixture drugs. Co. applies its technology to the development of generic versions of drug products as well as to the discovery and development of new drugs. As of Dec 31 2006, products under Co.'s development program included: M-Enoxaparin , a generic version of Lovenox , a low molecular weight heparin (LMWH) used to prevent and treat deep vein thrombosis and acute coronary syndrome (ACS); M118 , a LMWH designed to provide improved clinical properties to treat patients with ACS; and M-Dalteparin , which is targeted to be a generic version of Fragmin , a LMWH product.
 Market CapDay's VolumeLast TradeChange
 -5,438,296$17.15-15.5173%
 
OTCBB:MYMXMymetics Corporation
 Mymetics is a biotechnology research and development company. Co. is engaged in fundamental and applied research in the area of human biology and medicine. Co.'s primary objective is to develop vaccines and therapies to prevent and treat the effects of certain retroviruses, including the human immunodeficiency virus (HIV), and the virus that leads to acquired immunodeficiency syndrome (AIDS). Additional applications of Co.'s research include potential treatments and/or vaccines for human on oncoviral leukemias, multiple sclerosis, and organ transplantation.
 Market CapDay's VolumeLast TradeChange
 $65M3,000$0.149-0.6667%
 
OTC PK:MZTHMZT Holdings, Inc.
 MZT Holdings is a biotechnology company engaged in the development, manufacture, marketing, distribution and licensing of cancer diagnostic technologies, products and services. Co. focuses on the early detection of various types of cancer. The products Co. develops are based on proprietary nuclear matrix protein (NMP) technology. Co.'s research focuses on finding differences in the types and amounts of proteins found in tissue, blood and urine in patients with and without cancer. In addition, Co. designs products to detect these differences and to generate medically useful information in order to assist physicians in their diagnosis and treatment of patients.
 Market CapDay's VolumeLast TradeChange
 -2,000$0.03-14.2858%
 
NASDAQ:NABINABI BIOPHARMA
 Nabi Biopharmaceuticals develops and markets products for medical conditions in the areas of transplantation, infectious disease, nicotine addiction and hematology/oncology. At Dec 30 2006, Co. marketed two products: Nabi-HB [Hepatitis B Immune Globulin (Human)], a human polyclonal antibody product indicated to prevent hepatitis B infection following accidental exposure to hepatitis B virus, and Aloprim [Allopurinol sodium (for injection)], for the treatment of chemotherapy-induced hyperuricemia, or elevated uric acid levels, for patients with leukemia, lymphoma or solid organ tumors. Co. also has various products in clinical development, such as vaccines and antibody-based therapies.
 Market CapDay's VolumeLast TradeChange
 $221M100,674$5.60-2.6087%
 
OTCBB:NNANNaturalNano, Inc.
 NaturalNano is a development stage company engaged in the discovery, refinement and commercialization of naturally occurring nanoscale materials. Co.'s present activities are directed toward research, development, production and marketing of its proprietary technologies relating to the treatment and separation of nanotubes from halloysite clay and the development of related commercial applications for material additives for polymers, plastics and composites, health and beauty and household products, and agrichemical products.
 Market CapDay's VolumeLast TradeChange
 -56,000$0.0043-4.4445%
 
OTC PK:NAWLNatureWell, Inc.
 Naturewell is engaged primarily in the research and development of proprietary healthcare products intended for a variety of conditions. Co.'s primary focus is on the distribution and sale of its migraine medication, MIGRASPRAY , a homeopathic over-the-counter drug used for the treatment and prevention of migraine headaches. Co. outsources its manufacturing, warehousing and major distribution activities to third party vendors. MIGRASPRAY , is a patented, clinically tested, over-the-counter homeopathic drug for the fast relief and prevention of the symptoms of migraine headaches.
 Market CapDay's VolumeLast TradeChange
 $0M0$0.00010.0%
 
NASDAQ:NEOGNEOGEN
 Neogen develops, manufactures and markets various products for food safety testing and animal health applications. Co. operates in two segments: Food Safety and Animal Safety. The Food Safety segment primarily provides diagnostic test kits and complementary products such as dehydrated culture media that detect dangerous and/or unintended substances in human food and animal feed. The Animal Safety segment develops, produces and markets pharmaceuticals, rodenticides, disinfectants, vaccines, veterinary instruments, topicals, and diagnostic products to the animal safety market. Co.'s products are marketed by company sales personnel, distributors and a number of large farm supply retail chains.
 Market CapDay's VolumeLast TradeChange
 -42,142$29.10-2.7082%
 
OTC PK:NEOLNeoPharm, Inc.
 NeoPharm is a biopharmaceutical company engaged in the research, development and commercialization of drugs for the treatment of cancer. Co. has built a drug portfolio based on its two proprietary technology platforms: the NeoLipid liposomal drug delivery system, and a tumor-targeting toxin platform. As of Dec 31 2006, Co. had four drug product candidates in various stages of clinical development for the treatment of cancer. Co.'s core drug product candidate is CINTREDEKIN BESUDOTOX , a tumor-targeting toxin being developed as a treatment for glioblastoma multiforme, which is a form of brain cancer.
 Market CapDay's VolumeLast TradeChange
 -0$0.350.0%
 
NYSE:NEOPNeoProbe Corp.
 Neoprobe is a biomedical company focused on developing and commercializing products that enhance patient care and improve patient outcome by addressing the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Co. is engaged in research and clinical development of radiopharmaceutical and medical device technologies related to the intraoperative diagnosis and treatment of cancers, including its proprietary RIGS (radioimmunoguided surgery technology). Co. is also commercializing the Quantix line of blood flow measurement devices for a variety of diagnostic and surgical applications in the cardiac and vascular management arena.
 Market CapDay's VolumeLast TradeChange
 -55,574$2.010.0%
 
OTC PK:NTECNeose Technologies, Inc.
 Neose Technologies is a biopharmaceutical company which develops therapeutic proteins. As of Dec 31 2006, Co.'s key drug development portfolio consisted of GlycoPEG-EPO (NE-180), a long-acting version of erythropoietin produced in insect cells, prescribed to stimulate production of red blood cells for the treatment of anemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy and for the treatment of anemia associated with chronic kidney disease, including patients on dialysis and patients not on dialysis; and GlycoPEG-GCSF, a long-acting version of granulocyte colony stimulating factor, prescribed to stimulate production of neutrophils (a type of white blood cell).
 Market CapDay's VolumeLast TradeChange
 -0$0.0110.0%
 
NASDAQ:NEPTNEPTUNE TECH&BIORES
 Neptune Technologies & Bioresources is engaged in the research, development and commercialization of products derived from marine biomasses for the nutraceutical, pharmaceutical and cosmetics industries. Co. utilizes its exclusive process, Neptune OceanExtract , to exploit abundant and under-exploited marine species to extract bio-active ingredients such as polyunsaturated fatty acids, phospholipids and antioxidants that contribute to human wellness. Co. also carries out medical research and projects included in the applied research portfolio relating to cardiovascular and neuro-degenerative diseases, and rheumatoid arthritis.
 Market CapDay's VolumeLast TradeChange
 -4,208$1.38-0.7195%
 
OTC PK:NTMENetMed, Inc.
 Co.'s sole business activity during 2001, through its majority owned subsidiary OxyNet, Inc., involved research and development activities associated with a proprietary ceramic-based technology for separation of oxygen from ambient air and other gases. These activities were suspended effective Dec. 31, 2001, pending efforts to locate a prospective licensee or development partner.
 Market CapDay's VolumeLast TradeChange
 -0$0.00010.0%
 
More Pages: Page: 1 2 3 4 5 (6) 7 8 9 10 11
More

The term Market Sector is used to describe a set of businesses that are buying and selling such similar goods and services that they are in direct competition with each other. Analysts divide the stock market itself into market sectors so that shares of companies that are in direct competition are listed alongside each other.

In the bond market it refers to the division of the market by the type of issuer. E.g. government, state, corporate, or utility.

Markets are split into sectors using the Global Industry Classification Standard.

Home | Blogs | Savings Calculator | Tools | Contact Us | Disclosure | Site Map | Sign UpCopyright 2014
SmallCapWatch, LLC.
Never invest based soley on information from this website or our e-mail and IM alerts